Search

Your search keyword '"Bourque J"' showing total 300 results

Search Constraints

Start Over You searched for: Author "Bourque J" Remove constraint Author: "Bourque J"
300 results on '"Bourque J"'

Search Results

1. Normative modelling of brain morphometry across the lifespan with CentileBrain: algorithm benchmarking and model optimisation

4. An analysis-ready and quality controlled resource for pediatric brain white-matter research

6. Neovaginal squamous cell carcinoma in a transgender woman: Case report, treatment insights, and literature review

9. Abstracts

10. Subcortical volumes across the lifespan: Data from 18,605 healthy individuals aged 3-90 years

11. Cortical thickness across the lifespan: Data from 17,075 healthy individuals aged 3-90 years

12. Greater male than female variability in regional brain structure across the lifespan

13. Greater male than female variability in regional brain structure across the lifespan

14. Subcortical volumes across the lifespan: Data from 18,605 healthy individuals aged 3-90 years

15. Cortical thickness across the lifespan: Data from 17,075 healthy individuals aged 3-90 years

19. Cortical thickness across the lifespan: Data from 17,075 healthy individuals aged 3–90 years

20. QSIPrep: an integrative platform for preprocessing and reconstructing diffusion MRI data

22. Subcortical volumes across the lifespan: Data from 18,605 healthy individuals aged 3–90 years

32. High sustained virologic response rates in patients with chronic hepatitis C virus GT1, 2 or 3 infection following 16 weeks of MK-3682/grazoprevir/ruzasvir plus ribavirin after having failed 8 weeks of a triplet drug regimen (Part C of C-CREST-1 & 2).

34. High Sustained Virologic Response (SVR) Rates in Patients with Chronic HCV GT1, 2 or 3 Infection Following 16 Weeks of MK-3682/Grazoprevir/MK-8408 Plus Ribavirin After Failure of 8 Weeks of Therapy (Part C of C-CREST-1 & 2)

35. High sustained virologic response rates in patients with chronic hepatitis C virus GT1, 2 or 3 infection following 16 weeks of MK-3682/grazoprevir/ruzasvir plus ribavirin after having failed 8 weeks of a triplet drug regimen (Part C of C-CREST-1 & 2)

36. High sustained virologic response (SVR) rates in patients with chronic HCV GT1, 2 or 3 infection following 16 weeks of MK-3682/Grazoprevir/MK-8408 plus ribavirin after failure of 8 weeks of therapy (part C of C-CREST-1 &2).

43. THU-264 - High sustained virologic response rates in patients with chronic hepatitis C virus GT1, 2 or 3 infection following 16 weeks of MK-3682/grazoprevir/ruzasvir plus ribavirin after having failed 8 weeks of a triplet drug regimen (Part C of C-CREST-1 & 2)

Catalog

Books, media, physical & digital resources